Медицинская литература. Новинки

 

 

 

 

 

 

ЛЕЧЕНИЕ ИНФИЛЬТРАТИВНОЙ ОФТАЛЬМОПАТИИ

Вы можете загрузить полный текст статьи в формате pdf

Инфильтративная офтальмопатия – наиболее частое экстратиреоидное проявление аутоиммунных заболеваний щитовидной железы. В 3–5% случаев она имеет тяжелое течение и требует назначения специальной терапии. Существование большого количества способов лечения офтальмопатии и появление новых свидетельствуют об отсутствии достаточно эффективного метода ее лечения. В настоящем обзоре предпринята попытка систематизировать имеющиеся данные. Также в обзоре представлены рекомендации консенсуса European Group on Graves' Orbitopathy (EUGOGO) по лечению офтальмопатии.

Ключевые слова:
инфильтративная офтальмопатия, эндокринная офтальмопатия, лечение.

Литература:
1. Бровкина А.Ф. Эндокринная офтальмопатия. М.: Гоэтар-Мед, 2004.
2. Залевская А.Г., Благосклонная Я.В. Случай тяжелой офтальмопатии при эутиреозе // Пробл. эндокринол. 1985. №6. С. 40–41.
3. Balazs C., Kiss E., Vamos A., Molnar I, Farid N.R. 1998 Beneficial
effect of pentoxyfilline on thyroid-associated ophthalmopathy // J. Clin. Endocrinol. Metab. V. 82. P. 1999–2002.
4. Bartalena L., Marcocci C., Pinchera A. Cytokine antagonists: new ideas for the management of Graves` ophthalmopathy // J. Clin. ndocrinol. Metab. 1996. V. 81. P. 446–448.
5. Bartalena L., Marcocci C., Tanda M.L. et al. Relation between therapy for hyperthyroidism and the course of Graves` ophtalmopathy // N. Engl. J. Med. 1998. V. 338. P. 73–78.
6. Bartalena L., Marcocci C., Manetti L., Tanda M.L. et al. Orbital radiotherapy for Graves` ophtalmopathy // Thyroid. 1998. V. 8. P. 439–441.
7. Bartalena L., Pinchera A., Marcocci C. Management of Graves` ophtalmopathy: reality and perspectives // Endocr. Rev. 2000. V. 21. P. 168–199.
8. Bartalena L., Marcocci C., Pinchera A. Graves` ophtalmopathy: a preventable disease. 2002. V. 146. P. 457–461.
9. Bartalena L. Glucocorticoids for Graves` ophtalmopathy: how and when // J. Clin. Endocrinol. Metab. 2005. V. 90. P. 5497–5499.
10. Bartalena L., Baldeschi L., Dickinson A.J. et al. Consensus statement of the European Group on Graves` orbitopathy (EUGOGO) on management of Graves` orbitopathy // Thyroid. 2008. V. 18. V. 3. P. 333–345.
11. Bartley G.B., Fatourechi V. et al. Long-term followup of Graves'
ophthalmopathy in an incidence cohort // Ophthalmology. 1996. V. 103. P. 958–962.
12. Chang T.C., Kao S. C.S., Huang K.M. Octreotide and Graves` ophtalmopathy and pretibal myxoedema // Br. Med. 1992. V. 304. P. 580.
13. Dandona P. Methylprednisolone and Graves` ophtalmopathy // Br. Med. J. 1989. V. 298. P. 830.
14. Guy J., Fagien S., Donovan J. P., Rubin M. L. Methylprednisolone
pulse therapy in severe dysthyroid optic neuropathy // Ophthalmology. 1989. V. 96. P. 1048–1052.
15. Hiromatsu Y., Kojima K., Ishisaka N. et al. Role of magnetic resonance imaging in thyroid-associated ophtalmopathy: its predictive value for therapeutic outcime of immunosuppressive therapy // hyroid. 1992. V. 2. P. 299–305.
16. Hiromatsu Y., Tanaka K., Sato M. et al. Intravenous methylprednisolone pulse therapy of Graves` ophthalmopathy // Endocr. J. 1993. V. 40. P. 63–72.
17. Jarhult J., Rudberg C., Larsson E., Selvander H. et al. Graves` disease with moderatesevere endocrine ophthalmopathy – long term results of a prospective, randomozed study of total or subtotal thyroid resection // Thyroid. 2005. V. 15. P. 1157–1164.
18. Kauppinen-Makelin R., Karmi A., Leinonen E. et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroidassociated ophthalmopathy // Acta Ophtalmol. Scand. 2002. V. 80. P. 316–321.
19. Kahaly G., Schrezenmeir J., Krauze U. et al. Ciclosporin and prednisone vs. Prednisone in treatment of Graves` ophthalmopathy: a controlled, randomized and prospective study. // Eur. J. Clin. Invest. 1986. V. 16. P. 415–422.
20. Kahaly G., Diaz M., Just M. et al. Role of ostreoscan and correlation with MR imaging in Graves` ophtalmopathy // Thyroid. 1995. V. 5. P. 107–111.
21. Kahaly G.J., Rosler H. P., Pitz S., Hommel G. Low-versus high-dose
radiotherapy for Graves` ophtalmopathy: a randomized, single dlind trial // J. Clin Endocrinol. Metab. 2000. V. 85. P. 102–108.
22. Kahaly G. J., Pitz S., Hommel G., Dittmar M. Randomized, singleblind trial of intravenous versus oral steroid monotherapy in Graves` ophtalmopathy // J. Endocrinol. Metab. 2005. V. 90. P. 5234–5240.
23. Kendall-Taylor P., Crombie A.L., Stephenson A.M. et al. Intravenous methylprednisolone in the treatment of Graves` ophtalmopathy // Br. Med. J. 1988. V. 297. P. 1574–1578.
24. Krassas G. E., Dumas A., Pontikides N., Kaltsas T. Somatostatin
receptor scintigraphy andoctreotide treatment in patients with thyroid eye disease // Clin. Endocrinol. 1995. V. 42. P. 571–580.
25. Krassas G.E., Kaltsas T., Dumas A., Pontikides N., Tolis G. Lanreotide in the treatment of patients with thyroid eye disease // Eur. J. Endocrinol. 1997. V. 136. P. 416–422.
26. Krassas G. E., Wiersinga W.M. Modern conceptions of diagnostic and management of TAO // Thyroid Int. 2005. V. 4. P. 1–20.
27. Le Moli R., Baldeschi L., Seed P. et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves` ophtalmopathy // Thyroid. 2007. V. 12. P. 357–362.
28. Macchia P. E., Bagattini M., Lupoli G. et al. High-dose intravenous
corticosteroid therapy for Graves` ophtalmopathy // J. Endocrinol. Invest. 2001. V. 24. P. 152–158.
29. Marcocci C., Bartalena L. et al. Orbital cobalt irradiation combined
with retrobulbar or systemic corticosteroids for Graves'ophthalmopathy: a comparative study // Clin. Endocrinol. 1987. V. 27. P. 33–42.
30. Marino M., Morabito E., Brunetto M.R. et al. Acute and severe liver
damage associated with intravenous glucocorticoid pulse therapy in patients with Graves` ophtalmopathy // Thyroid. 2000. V. 14. P. 403–406.
31. Marquez S.D., Lum B.L., McDougall I.R. et al. Long-term results
of irradiation for patients with Graves` ophtalmopathy // Int. J. Rad. Oncol. Biol. Phys. 2001. V. 51. P. 766–774.
32. Menconi F., Marino M., Pinchera A., Rocchi L. et al. Effects of total
thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves` ophtalmopathy treated with intravenous glucocorticoids // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 1653–1658.
33. Mourits M. P., Prummel M. F., Wiersina W. M., Koorneef L. Clinical activity score as a guide in the management of patients with Graves` ophtalmopathy // Clin. Endocrinol. 1997. V. 47. P. 9–14.
34. Nabipour I., Burger A., Moharreri M. Avicenna, the First to Discribe Thyroid-Related Orbitopathy // Thyroid. 2009. V. 19. 1. P. 7–8.
35. Nagayama Y., Izumi M., Kiriyama T. et al. Treatment of Graves` ophtalmopathy with high-dose intravennous methylprednisolone pulse therapy // Acta. Endocrinol. 1987. V. 116. P. 513–518.
36. Perros P., David R. et al. Azathioprine in the treatment of thyroidassociated ophthalmopathy // Acta. Endocrinol. 1990. V. 122 (1).
P. 8–12.
37. Pinchera A., Bartalena L., Chiovato L., Marcocci C. Radiotherapy
of Graves`ophthalmopathy. New York: Raven Press, 1984. P. 301–316.
38. Prummel M.F., Wiersinga W.M. Immunomodulatory treatment of
Graves` ophtalmopathy // Thyroid. 1998. V. 8. P. 543–546.
39. Prummel M.F., Wiersinga W.M. Smoking and risk of Graves` disease // JAMA. 1993. V. 269. P. 479–482.
40. Prummel M.F., Mourits M.P., Berghout A., Krenning E.P. et al.
Prednisone and cyclosporine in the treatment of severe Graves` ophtalmopathy // N. Engl. J. Med. 1989. V. 321. P. 1353–1359.
41. Prummel M.F., Wiersinga W.M., Mourits M.P. et al. Amelioration of eye changes of Graves` ophtalmopathy by achieving euthyroidism // Acta. Endocrinol. 1989. V. 121 (Suppl. 2). P. 185–189.
42. Prummel M.F., Wiersinga W.M., Mourits M.P. et al. Effect of abnormal thyroid function on the severity of Graves` ophtalmopathy // Arch. Intern. Med. 1990. V. 150. P. 1098–1101.
43. Prummel M.F., Mourits M.P., Blank L. et al. Randomised doubleblind trial of prednisone versus radiotherapy in Graves` ophtalmopathy // Lancet. 1993. V. 342. P. 949–954.
44. Raza A. Anti-TNF theraputies in rheumatoid arthritis, Crohn`s disease, sepsis and myelodysplatic syndromes // Microsc. Res. Tech. 2000. V. 50. P. 229–235.
45. Salvi M., Vannucchi G. et al. Rituximab in the treatment of thyroid
eye disease: science fiction? // Orbit. 2009. V. 28. P. 251-255.
46. Stamal F. G., Maciel R.M. et al. Colchicine in the treatment oft he
inflammatory phase of Graves' ophthalmopathy: a prospective and randomized trial with prednisolone // Acta. Bras. Oftalmol. 2006. V. 69. P. 811–816.

Treatment of Graves' ophthalmopathy

Graves' ophthalmopathy is one of most frequent extrathyroid manifestation of autoimmune thyroid diseases. In 3–5% cases it has severe progress and requires specific therapy. There are many methods of treatment and it's getting more and more, but that demonstrate no sufficient effectiveness. In this review was made an essay to systematize current data. Also guidelines of consensus EUGOGO for treatment of ophtalmopathy is represented here.

Keywords:
infiltrative ophthalmoparthy, endocrine ophthalmoparthy, trearment.